



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known	
				Application Number	09/921,143-Conf. #6449
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	August 3, 2001
				First Named Inventor	Timothy A. Coleman
				Art Unit	1636
				Examiner Name	C.X. Qian
Sheet	1	of	1	Attorney Docket Number	PF112P6

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ -Kind Code ⁵ (if known)				
ca	GX	WO-99/20749		04-29-1999	Medical Research Counsel		
	GY	WO-97/08320		03-06-2004	Morphosys Gesellschaft Fur Proteinoptimier Ung MBH		
	GZ	WO-98/55619		12-10-1998	ASAT AG Applied Science & Technology		
	HA	WO-99/02545		01-21-1999	Novopharm Biotech, Inc.		
	HB	WO-97/00271		01-03-1997	The Regents of the University of California		
	HC	WO-97/19694		06-05-1997	Amgen, Inc.		
	HD	WO-00/73430		12-07-2000	Max-Delbruck-Centrum Fur Molekulare Medizin		
	HE	WO-01/58956		08-16-2001	BASF AG, et al.		
	HF	WO-01/57226		08-09-2001	BRIEN, et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
ca	HG	EBI Accession No. AAW27553, KNAPPIK et al., "Human Ab heavy chain variable region VH3 consensus" (Jan. 23, 1998).			
	HH	YANG et al., "Flk-1, a Receptor for Vascular Endothelial Growth Factor (VEGF), Is Expressed by Retinal Progenitor Cells," <i>J. Neuroscience</i> , 16(19):6089-6099 (Oct. 1, 1996).			
	HI	GERHARDINGER, et al., "Expression of Vascular Endothelial Growth Factor in the Human Retina and in Nonproliferative Diabetic Retinopathy," <i>Am. J. Pathol.</i> , 152(6):1453-1462 (Jun. 6, 1998).			
	HJ	YOUREY et al., "Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells," <i>J. Neuroscience</i> , 20(18.):6781-6788 (Sept. 15, 2000).			
	HK	YOUREY et al., "Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells," <i>Molecul. Biol. Cell</i> , 10(Suppl.):39a (Nov. 1999) and 39 th Ann. Mtg. Am. Soc. Cell Biol., Wash, DC, (Dec. 11-15, 1999) (abstract (227) only).			
	HL	Supplementary European Search Report, Application No. EP 02 72 6730, mailed October 25, 2004.			
	HM	Supplementary European Search Report, Application No. EP 00 90 5992, mailed November 8, 2004.			
	HN	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129 (1995).			
✓	HO	WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204:289-300 (1993).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	7/8/05
--------------------	--	-----------------	--------



PATENT TRADEMARK OFFICE

U.S. Patent and Trademark Office

Under the Patent Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/921,143-Conf. #6449
				Filing Date	August 3, 2001
				First Named Inventor	Timothy A. Coleman
				Art Unit	1636
				Examiner Name	C. X. Qian
Sheet	1	of	1	Attorney Docket Number	PF112P6

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
ca	GU	SCHRATZBERGER et al., "Reversal of experimental diabetic neuropathy by VEGF gene transfer," <i>J. Clin. Invest.</i> , 107(9):1083-1092 (May 2001)				
y	GV	VALE et al., "Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients with Chronic Myocardial Ischemia," <i>Circulation</i> , 103:17:2138-2143 (May 1, 2001)				
1'	GW	European Supplementary Search Report, Application No. EP 01 96 3814, mailed July 14, 2004				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	7/8/05
-----------------------	--	--------------------	--------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	09/921,143-Conf. #6449
				Filing Date	August 3, 2001
				First Named Inventor	Tim Coleman
				Art Unit	1636
				Examiner Name	C. X. Qian
				Attorney Docket Number	PF112P6
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
W	HP	6,130,071	10-10-2000	Alitalo et al.	
	HQ	6,221,839	04-24-2001	Alitalo et al.	
	HR	6,245,530	06-12-2001	Alitalo et al.	
	HS	6,403,088	06-11-2002	Alitalo et al.	
	HT	08/340011	11-14-1994	Alitalo et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
W	HU	WO-91/02058	02-21-1991	Scios Nova Inc.		
V	HV	WO-95/24473	09-14-1995	Human Genome Sciences, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Examiner Signature		Date Considered	7/8/05
-----------------------	--	--------------------	--------




PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2008. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/921,143-Conf. #6449
				Filing Date	August 3, 2001
				First Named Inventor	Tim Coleman
				Art Unit	1636
				Examiner Name	C. X. Qian
Sheet	2	of	3	Attorney Docket Number	PF112P6

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
CA	HW	ALTSHULER et al., "Taurine promotes the differentiation of a vertebrate retinal cell type in vitro," <i>Development</i> , 119:1317-1328 (1993).		
	HX	BOCKER-MEFFERT et al., "Erythropoietin and VEGF Promote Neural Outgrowth from Retinal Explants in Postnatal Rats," <i>Invest. Ophthalmol. Vis. Sci.</i> , 43(6):2021-2026 (2002).		
	HY	GAIL M. SEIGEL, "The golden age of retinal cell culture," <i>Molec. Vis.</i> 5:4 (1999).		
	HZ	HANNINK et al., "Deletions in the C-Terminal Coding Region of the v-sis Gene: Dimerization Is Required for Transformation" <i>Mol. And Cellular Biol.</i> 1304-1314 (1986).		
	IA	HIRAI et al., "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endometrial Carcinoma," <i>Gynecol. Oncol.</i> 80:181-188 (2001).		
	IB	KELLEY et al., "Regulation of a Proliferation and Photoreceptor Differentiation in Fetal Human Retinal Cell Cultures," <i>Invest. Ophthalmol. Vis. Sci.</i> 36(7):1280-1289 (1995).		
	IC	MAGLIONE et al., "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-931 (1993).		
	ID	NGO et al., The Protein Folding Problem and Tertiary Structure Prediction, Kenneth Merz, Jr. and Scott LeGrand, eds., Birkhauser, Boston, pp. 492-495 (1994).		
	IE	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , 79(6):1979-1983 (Mar. 1982)		
	IF	SCHULZ-KEY et al., "Ciliary Neurotrophic Factor as a Transient Negative Regulator of Rod Development in Rat Retina," <i>Invest. Ophthalmol. Vis. Sci.</i> 43(9):3099-3108 (2002).		
	IG	STACKER et al., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> , Vol. 17, pp. 1-11 (1999).		
	IH	JOOSTEN et al., "The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi," <i>Microbial Cell Factories</i> 2:1 (Jan. 30, 2003).		
	II	SKERRA et al., "Assembly of a functional immunoglobulin Fv fragment in <i>Escherichia coli</i> ," <i>Science</i> 240(4855):1038-1041 (May 20, 1988).		
	IJ	BETTER et al., "Escherichia coli secretion of an active chimeric antibody fragment," <i>Science</i> 240(4855):1041-1043 (May 20, 1988).		
	IK	HOUCK, et al., "The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA." <i>Molecular Endocrinology</i> . 5(12):1806-14 (1991).		
	IL	COLWELL, et al., "Method for generating a high frequency of hybridomas producing monoclonal IgA antibodies." <i>Methods Enzymol.</i> 121:42-51 (1986).		

Examiner Signature		Date Considered	7/18/05
--------------------	--	-----------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/921,143-Conf. #6449
				Filing Date	August 3, 2001
				First Named Inventor	Tim Coleman
				Art Unit	1636
				Examiner Name	C. X. Qian
Sheet	3	of	3	Attorney Docket Number	PF112P6

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
CA	IM	GenBank Accession No. S08167, PAULSSON et al., 1990.		
	IN	Supplementary Partial European Search Report, Application No. EP 02 72 6730, mailed August 4, 2004.		
	IO	Supplementary Partial European Search Report, Application No. EP 02 72 1715, mailed January 10, 2005.		
	IP	Supplementary Partial European Search Report, Application No. EP 02 72 1715, mailed October 22, 2004.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	7/18/05
-----------------------	--	--------------------	---------